Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug-Reference-Cited by-同舟云学术

Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug

Published:2015 Issue: Volume:2015 Page:1-9
ISSN:1687-6121
Container-title:Gastroenterology Research and Practice
language:en
Short-container-title:Gastroenterology Research and Practice

Author:

Perrotta Cristiana¹,Pellegrino Paolo¹,Moroni Eliana²,De Palma Clara¹,Cervia Davide¹³,Danelli Piergiorgio²,Clementi Emilio¹⁴

Affiliation:

1. Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, Italy

2. Unit of General Surgery, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, Italy

3. Department for Innovation in Biological, Agro-Food and Forest Systems, Università della Tuscia, 01100 Viterbo, Italy

4. Scientific Institute, IRCCS Eugenio Medea, 23842 Bosisio Parini, Italy

Abstract

Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn’s disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.

Funder

Ministero dell’Istruzione, Università e Ricerca

Publisher

Hindawi Limited

Subject

Gastroenterology,Hepatology

Link

http://downloads.hindawi.com/journals/grp/2015/456895.pdf

Reference120 articles.

1. IBD—genes, bacteria and new therapeutic strategies

2. Current issues in inflammatory bowel disease neoplasia

3. Conventional Medical Management of Inflammatory Bowel Disease

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoparticles encapsulated in Abelmoschus esculentus polysaccharide-based pellets as colon targeting approach;Journal of Microencapsulation;2024-08-20

2. Desloratadine via its anti-inflammatory and antioxidative properties ameliorates TNBS-induced experimental colitis in rats;Immunopharmacology and Immunotoxicology;2024-05-30

3. Weissella koreensis KJ, Which Increases Gut Tight Junction Protein Expression, Alleviates TNBS-Induced Colitis by Suppressing Inflammatory Cytokines;Microbiology Research;2024-05-08

4. The aminosalicylate - folate connection;Drug Metabolism Reviews;2024-01-02

5. Oral delivery of pH-sensitive nanoparticles loaded Celastrol targeting the inflammatory colons to treat ulcerative colitis;Journal of Tissue Engineering;2024-01